Eye Meds Now

 Quick Ophthalmic Drug Search

223 items found
AMOXICILLIN/CLAVULANATE (amoxicillin/clavulanate potassium (125 mg/5 mL; 200 mg/5 mL; 250 mg/5 mL; 400 mg/5 mL: 600 mg/5 mL) oral suspension; (200 mg; 400 mg) chewable tablets; (250 mg; 500 mg; 875 mg) tablets)
Prescription
Ophthalmic Solution
Oral
Chewable Tablets
Tablets
Antibiotics
Indications/Usage:

Indicated for the treatment of: skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocyctitis.

This medication has a broad FDA approval for "skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocystitis:

  • Adults:
    • 500 mg every 8 – 12 hours for 7 – 10 days.
    • Dosage based on amoxicillin component.
  • Children ≥ 3 months:
    • 25 mg/kg/day divided every 12 hours for 10 – 14 days.
    • Pediatric patients weighing ≥ 40 kg should be dosed according to adult recommendations.
    • Dosage based on amoxicillin component.
  • Neonates and infants < 3 months:
    • Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended dose of amoxicillin/clavulanate is 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Clavulanate elimination is unaltered in this age group. Experience with the 200 mg/5 mL formulation in this age group is limited and, thus, use of the 125 mg/5 mL oral suspension is recommended.
  • Consult package insert for additional information.
Dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Oral suspension:
    • 125 mg/5 mL suspension (31.25 mg clavulanic acid) (50 mL, 75 mL, 100 mL bottles)
    • 200 mg/5 mL suspension (28.5 mg clavulanic acid) (50 mL, 75 mL, 100 mL bottles)
    • 250 mg/5 mL suspension (62.5 mg clavulanic acid) (75 mL, 100 mL, 150 mL bottles)
    • 400 mg/5 mL suspension (57 mg clavulanic acid) (50 mL, 75 mL, 100 mL bottles)
    • 600 mg/5 mL suspension (42.9 mg clavulanic acid) (75 mL, 125 mL, 200 mL bottles)
  • Chewable tablets:
    • 200 mg chewable tablets (28.5 mg clavulanic acid)
    • 400 mg chewable tablets (57 mg clavulanic acid)
  • Tablets:
    • 250 mg tablets (125 mg clavulanic acid)
    • 500 mg tablets (125 mg clavulanic acid)
    • 875 mg tablets (125 mg clavulanic acid)

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Oral suspension:
    • SHAKE ORAL SUSPENSION WELL BEFORE USING.
    • Store under refrigeration.
    • Discard after 10 days.
  • Tablets (including chewable):
    • Store at or below 77°F (25°C).


AMOXIL (amoxicillin (250; 500 mg) capsules; (500 mg; 875 mg) tablets; (125 mg; 250 mg) chewable tablets; (125 mg/5 mL; 200 mg/5 mL; 250 mg/5 mL; 400 mg/5 mL) oral suspension)
Prescription
Oral
Capsules
Chewable Tablets
Oral Suspension
Tablets
Antibiotics
Indications/Usage:

Indicated for the treatment of infections of the skin and skin structure due to susceptible (ONLY ß-lactamase-negative) strains of the following designated microorganisms: Streptococcus spp. (α- and ß-hemolytic strains only), Staphylococcus spp., or E. coli.

This medication has a broad FDA approval for "infections of the skin and skin structure." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "infections of the skin and skin structure." This is our medical opinion and may not be true in all clinical circumstances.

 


Typical Dosing:  

►Skin and skin structure infections:

  • Adults:
    • Mild/Moderate:
      • 500 mg every 12 hours or 250 mg every 8 hours.
    • Severe:
      • 875 mg every 12 hours or 500 mg every 8 hours.
    • Dosing for infections caused by less susceptible organisms should follow the recommendations for severe infections.
  • Children aged > 3 months:
    • The children’s dosage is intended for individuals whose weight is < 40 kg. Children weighing  40 kg should be dosed according to the adult recommendations.
    • Mild/Moderate:
      • 25 mg/kg/day in divided doses every 12 hours. OR
      • 20 mg/kg/day in divided doses every 8 hours.
    • Severe:
      • 45 mg/kg/day in divided doses every 12 hours. OR
      • 40 mg/kg/day in divided doses every 8 hours. 
    • Dosing for infections caused by less susceptible organisms should follow the recommendations for severe infections.
  • Neonates and infants aged ≤ 12 Weeks (≤ 3 Months):
    • Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended upper dose of AMOXIL is 30 mg/kg/day divided every 12 hours.
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • Capsules
    • 250 mg capsules
    • 500 mg capsules
  • Tablets
    • 500 mg tablets
    • 875 mg tablets
  • Chewable tablets
    • 125 mg chewable tablets
    • 250 mg chewable tablets
  • Oral suspension
    • 125 mg/5 mL (80 mL, 100 mL, 150 mL bottles)
    • 200 mg/5 mL (50 mL, 75 mL, 100 mL bottles)
    • 250 mg/5 mL (80 mL, 100 mL, 150 mL bottles)
    • 400 mg/5 mL (50 mL, 75 mL, 100 mL bottles)

Preservatives:  

None listed in package insert (capsules, tablets, chewable tablets); sodium benzoate (suspension, pediatric drops)


Storage:  
  • Store at or below 68°F (20°C).
    • Capsules
    • Unreconstituted powder
  • Store at or below 77°F (25°C).
    • Unreconstituted powder
    • Chewable tablets
    • Tablets
  • Keep bottle tightly closed.
  • Any unused portion of reconstituted suspensions must be discarded after 14 days.
  • Refrigeration preferable, but not required.


APRACLONIDINE (apraclonidine hydrochloride (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Alpha Agonists
Indications/Usage:

Indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction. Patients on maximally tolerated medical therapy who are treated with Apraclonidine Ophthalmic Solution to delay surgery should have frequent follow-up examinations and treatment should be discontinued if the IOP rises significantly.

The addition of Apraclonidine Ophthalmic Solution to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because Apraclonidine Ophthalmic Solution is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP.

The IOP lowering efficacy of Apraclonidine Ophthalmic Solution diminishes over time in some patients. This loss of effect, or tachyphylaxis, appears to be an individual occurrence with a variable time of onset and should be closely monitored. The benefit for most patients is less than 1 month.


Typical Dosing:  

►Short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional reduction of intraocular pressure (IOP): 

  • Instill 1 – 2 drops into the affected eye(s) 3 times daily.
  • Since Apraclonidine Ophthalmic Solution will be used with other ocular glaucoma therapies, an approximate 5 minute interval between instillation of each medication should be practiced to prevent washout of the previous dose.
  • NOT FOR INJECTION INTO THE EYE. NOT FOR ORAL INGESTION.

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C). 
  • Protect from freezing and light.
  • Retain in carton until time of use.


ATROPINE (atropine sulfate (1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Cycloplegics
Indications/Usage:

Indicated for: cycloplegia; mydriasis; penalization of the healthy eye in the treatment of amblyopia.


Typical Dosing:  

Cycloplegia; mydriasis; penalization of the healthy eye in the treatment of amblyopia:

  • In individuals  3 months of age: 
    • Instill 1 drop topically to the cul-de-sac of the conjunctiva, 40 minutes prior to the intended maximal dilation time. 
  • In individuals 3 years of age: 
    • Doses may be repeated up to twice daily as needed.

How Supplied:  
  • Ophthalmic solution:
    • 2 mL bottles
    • 5 mL bottles
    • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Keep tightly closed.


AUGMENTIN (amoxicillin/clavulanate potassium (125 mg/5 mL; 250 mg/5 mL; 600 mg/5 mL) oral suspension; (500 mg; 875 mg) tablets)
Prescription
Oral
Oral Suspension
Tablets
Antibiotics
Indications/Usage:

Indicated for the treatment of: skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocyctitis.

This medication has a broad FDA approval for "skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Skin infections; sinusitis; hordeolum; preseptal cellulitis; dacryocystitis:

  • Adults:
    • 500 mg every 8 – 12 hours for 7 – 10 days.
    • Dosage based on amoxicillin component.
  • Children ≥ 3 months:
    • 25 mg/kg/day divided every 12 hours for 10 – 14 days.
    • Pediatric patients weighing ≥ 40 kg should be dosed according to adult recommendations.
    • Dosage based on amoxicillin component.
  • Neonates and infants < 3 months:
    • Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended dose of AUGMENTIN is 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Clavulanate elimination is unaltered in this age group. Experience with the 200 mg/5 mL formulation in this age group is limited and, thus, use of the 125 mg/5 mL oral suspension is recommended.
  • Consult package insert for additional information.
Dosing is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Oral suspension:
    • 125 mg/5 mL suspension (31.25 mg clavulanic acid) (50 mL, 75 mL, 100 mL bottles)
    • 250 mg/5 mL suspension (62.5 mg clavulanic acid) (75 mL, 100 mL, 150 mL bottles)
    • 600 mg/5 mL suspension (42.9 mg clavulanic acid) (75 mL, 125 mL, 200 mL bottles)
  • Tablets:
    • 500 mg tablets (125 mg clavulanic acid)
    • 875 mg tablets (125 mg clavulanic acid)

Preservatives:  

None listed in package insert.


Storage:  
  • Oral suspension:
    • SHAKE ORAL SUSPENSION WELL BEFORE USING.
    • Store under refrigeration.
    • Discard after 10 days.
  • Tablets:
    • Store at or below 77°F (25°C).


AVASTIN (bevacizumab (25 mg/mL) injection solution)
Prescription
Injectable
Intravitreal
VEGF Inhibitors
Indications/Usage:

Used for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization, or choroidal neovascularization due to presumed ocular histoplasmosis.

This medication is not FDA approved for ophthalmic conditions. Under our interpretation of supporting peer-reviewed studies we have linked this medication with conditions we understand may benefit from off-label use of this medication. This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Macular degeneration, wet age-related or choroidal retinal neovascularization:

  • 1.25 mg (0.05 mL) intravitreal injection monthly for 3 months, then monthly or as needed.

►Macular edema following retinal vein occlusion:

  • 1.25 mg (0.5 mL) intravitreal injection once.
  • Repeat at 1 – 3 month intervals if foveal thickness 250 mcm or greater or if persistent or recurrent macular edema.

►Diabetic macular edema or diabetic retinopathy:

  • 1.25 mg (0.5 mL) intravitreal injection at baseline.
  • Repeat at 6 and 12 weeks. Additional injections at 6 week intervals up to a maximum of 9 injections in first 12 months.
Dosing based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • 100 mg/4 mL single-dose vials
  • 400 mg/16 mL single-dose vials

Preservatives:  

None listed in package insert.


Storage:  
  • Store refrigerated at 36° – 46°F (2° – 8°C) in the original carton until time of use to protect from light.
  • Do not freeze or shake the vial or carton.


Assistance: Payment Assistance

AZASITE (azithromycin (1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G*; Haemophilus influenzae; Staphylococcus aureus; Streptococcus mitis group; Streptococcus pneumonia.
*Efficacy for this orgaeptiblenism was studied in < 10 infections.


Typical Dosing:  

►Bacterial conjunctivitis caused by susceptible isolates of the listed microorganisms, recommended:

  • Instill 1 drop in the affected eye(s) twice daily, 8 – 12 hours apart for the first 2 days, then instill 1 drop in the affected eye(s) once daily for the next 5 days.

How Supplied:  
  • 2.5 mL bottles

Preservatives:  

benzalkonium chloride, disodium edetate


Storage:  
  • Store unopened bottle under refrigeration at 36° – 46°F (2° – 8°C).
  • Once the bottle is opened, store at 36° – 77°F (2° – 25°C) for up to 14 days.
  • Discard after the 14 days.


AZELASTINE (azelastine hydrochloride (0.05%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Indicated for the treatment of itching of the eye associated with allergic conjunctivitis.


Typical Dosing:  

►Itching associated with allergic conjunctivitis, recommended:

  • Instill 1 drop into the affected eye(s) twice a day.

How Supplied:  
  • 6 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store upright between 36° – 77°F (2° –  25°C).


AZITHROMYCIN (azithromycin (250 mg; 500 mg; 600 mg) tablets; (100 mg/5 mL; 200 mg/5 mL) oral suspension)
Prescription
Oral
Oral Suspension
Tablets
Antibiotics
Indications/Usage:

Indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms: uncomplicated skin and skin structure infections in adults due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.

This medication has a broad FDA approval for "skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Skin/skin structure (uncomplicated): 

  • 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.

►Inclusion (chlamydial) conjunctivitis:

  • 1000 mg single dose.

►Hordeolum:

  • 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.
Dosing for inclusion (chlamydial) conjunctivitis and hordeolum are based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Tablets:
    • 250 mg tablets
    • 500 mg tablets
    • 600 mg tablets
  • Oral supension:
    • 100 mg/5 mL oral suspension (15 mL bottles)
    • 200 mg/5 mL oral suspension (15 mL, 22.5 mL, 30 mL bottles)

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Tablets:
    • Store at 59° – 86°F (15° – 30°C).
  • Suspension:
    • Store dry powder below 86°F (30°C).
    • Store constituted suspension between 41° – 86°F (5° – 30°C).
    • Discard when full dosing is completed.


AZOPT (brinzolamide (1%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Carbonic Anhydrase Inhibitors
Indications/Usage:

Indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma, recommended: 

  • Instill 1 drop into the affected eye(s) 3 times daily.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP.
  • If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 10 minutes apart.

How Supplied:  
  • 10 mL bottles
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 39° – 86°F (4° – 30°C). 


Assistance: Payment Assistance

BACITRACIN (bacitracin (500 units/g) ophthalmic ointment)
Prescription
Topical
Ointment
Antibiotics
Indications/Usage:

Indicated for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms.


Typical Dosing:  

►Superficial ocular infections involving the conjunctiva and/or cornea caused by susceptible organisms: 

  • Apply directly into the conjunctival sac 1 – 3 times daily.
  • In blepharitis all scales and crusts should be carefully removed and the ointment then spread uniformly over the lid margins.
  • Patients should be instructed to take appropriate measures to avoid gross contamination of the ointment when applying the ointment directly to the infected eye.

How Supplied:  
  • 1 g tubes
  • 3.5 g tubes

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


BACTRIM (sulfamethoxazole - trimethoprim (200 mg/40 mg per 5 mL) oral suspension; (400 mg/80 mg) single-strength tablets; (800 mg/160 mg) double-strength tablets)
Prescription
Oral
Oral Suspension
Tablets
Antibiotics
Indications/Usage:

Used in the treatment of lacrimal infections, preseptal cellulitis, and/or soft tissue infections.

This medication has a broad FDA approval for the treatment of "infections due to susceptible strains of bacteria." Under our interpretation of this indication we have linked this medication with conditions we understand may be "infections due to susceptible strains of bacteria." This is our medical opinion and may not be true in all clinical circumstances.


Typical Dosing:  

►Lacrimal infections, preseptal cellulitis, and/or soft tissue infections, recommended: 

  • Adults:
    • Double strength (Bactrim DS) tablets (800 mg/160 mg each):
      • Take 1 Bactrim DS tablet every 12 hours for 5 – 7 days.
    • Single strength (Bactrim) tablets (400 mg/80 mg each):
      • Take 2 Bactrim tablets every 12 hours for 5 – 7 days.
    • Oral suspension (200 mg/40 mg per 5 mL):
      • Take 20 mL oral suspension every 12 hours for 5 – 7 days.
  • Children ≥ 2 months:
    • Give 40 mg/kg/day sulfamethoxazole (8 mg/kg/day trimethoprim) divided every 12 hours for 5 – 7 days.
  • Dose adjustments for patients with impaired renal function, recommended:
    • CrCl > 30 mL/min: dose as usual.
    • CrCl 15 – 30 mL/min: dose at 50% of usual regimen.
    • CrCl < 15 mL/min: use not recommended.
Treatment duration based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Oral suspension:
    • 200/40 per 5 mL oral suspension: contains 200 mg sulfamethoxazole and 40 mg trimethoprim per 5 mL
  • Single strength tablets:
    • 400/80 tablets: each containing 400 mg sulfamethoxazole and 80 mg trimethoprim
  • Double strength tablets (Bactrim DS):
    • 800/160 tablets: each containing 800 mg sulfamethoxazole and 160 mg trimethoprim

Preservatives:  

alcohol, methylparaben, sodium benzoate (oral suspension); sodium benzoate (tablets).


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.


BEPREVE (bepotastine besilate (1.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis.


Typical Dosing:  

Itching associated with allergic conjunctivitis:

  • Instill 1 drop into the affected eye(s) twice a day.
  • Remove contact lenses prior to instillation.

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

benzalkonium chloride 


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


Assistance: Payment Assistance

BESIVANCE (besifloxacin (0.6%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Antibiotics
Indications/Usage:

Indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridians*; CDC coryneform group G; Corynebacterium pseudodiphtheriticum*; Corynebacterium striatum*; Haemophilus influenzae; Moraxella catarrhalis*; Moraxella lacunata*; Pseudomonas aeruginosa*; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis*; Staphylococcus lugdunensis*; Staphylococcus warneri*; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius*.

*Efficacy for this organism was studied in fewer than 10 infections


Typical Dosing:  

►Bacterial conjunctivitis caused by susceptible isolates of the listed bacteria: 

  • Invert closed bottle and shake once before use.
  • Instill 1 drop into the affected eye(s) 3 times daily, 4 – 12 hours apart, for 7 days.

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C). 
  • Protect from light.


Assistance: Payment Assistance

BETADINE (povidone-iodine (5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Other Medications
Indications/Usage:

Indicated for prepping of the periocular region (lids, brow, and cheek) and irrigation of the ocular surface (cornea, conjunctiva, and palpebral fornices).


Typical Dosing:  

Prepping of the periocular region (lids, brow, and cheek) and irrigation of the ocular surface (cornea, conjunctiva, and palpebral fornices):

  • While the inner surface and contents of the immediate container (i.e., bottle) are sterile, the outer surface of the bottle is not sterile. The use of the bottle in a sterile field should be avoided.
  • Make sure container is intact before use. To open, COMPLETELY TWIST OFF TAB, do not pull off.
  • Gently pour entire contents of bottle into a sterile prep cup. Saturate sterile cotton-tipped applicator to prep lashes and lid margins using 1 or more applicators per lid; repeat once.
  • Saturate sterile prep sponge or other suitable material to prep lids, brow and cheek in a circular ever-expanding fashion until the entire field is covered; repeat prep 3 times.
  • While separating the lids, irrigate the cornea, conjunctiva and palpebral fornices with BETADINE® 5% Sterile Ophthalmic Prep Solution using a sterile bulb syringe.
  • After the BETADINE® 5% Sterile Ophthalmic Prep Solution has been left in contact for 2 minutes, sterile saline solution in a bulb syringe should be used to flush the residual prep solution from the cornea, conjunctiva, and the palpebral fornices.

How Supplied:  
  • 30 mL ophthalmic prep bottles

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Single-use only.


BETAGAN (levobunolol hydrochloride (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Has been shown to be effective in lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension, recommended:

  • Starting dose: Instill 1 – 2 drops into the affected eye(s) once daily.
  • In patients with more severe or uncontrolled glaucoma, BETAGAN® 0.5% can be administered twice daily.
  • As with any new medication, careful monitoring of patients is advised.
  • Dosages above 1 drop of BETAGAN® 0.5% twice a day are not generally more effective.
  • If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with other ophthalmic IOP-lowering agents can be instituted. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Protect from light.


BETAXOLOL (betaxolol hydrochloride (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Indicated for the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with ocular hypertension or chronic open-angle glaucoma, recommended: 

  • Instill 1 – 2 drops into the affected eye(s) twice daily. 
  • In some patients, the IOP-lowering responses to betaxolol ophthalmic solution may require a few weeks to stabilize.
  • As with any new medication, careful monitoring of patients is advised. 
  • If the IOP of the patient is not adequately controlled on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine and/or carbonic anhydrase inhibitors can be instituted.

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles
  • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


BETIMOL (timolol hemihydrate (0.25%; 0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma, recommended:

  • Starting dose: Instill 1 drop of 0.25% Betimol® into the affected eye(s) twice a day.
  • If the clinical response is not adequate, the dosage may be changed to 1 drop of 0.5% solution in the affected eye(s) twice a day.
  • If the IOP is maintained at satisfactory levels, the dosage schedule may be changed to 1 drop once a day in the affected eye(s). Because of diurnal variations in IOP, satisfactory response to the once-a-day dose is best determined by measuring the IOP at different times during the day.
  • Since in some patients the IOP-lowering response may require a few weeks to stabilize, evaluation should include a determination of IOP after approximately 4 weeks of treatment.
  • Dosages above 1 drop of 0.5% Betimol® twice a day generally have not been shown to produce further reduction in IOP.
  • If the patient's IOP is still not at a satisfactory level on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted.

How Supplied:  
  • 0.25% ophthalmic solution:
    • 5 mL bottles
  • 0.5% ophthalmic solution:
    • 5 mL bottles
    • 10 mL bottles
    • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C). 
  • Do not freeze.
  • Protect from light.


BETOPTIC-S (betaxolol hydrochloride (0.25%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Beta Blocking Agents
Indications/Usage:

Indicated for the treatment of elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension: 

  • Shake well before using.
  • Instill 1 drop into the affected eye(s) 2 times daily. 
  • May be used alone or in combination with other IOP-lowering medications.

How Supplied:  
  • 10 mL bottles
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store upright at 36° – 77°F (2° – 25°C).
  • Shake well before using.


Assistance: Payment Assistance

BIMATOPROST (bimatoprost (0.03%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended: 

  • Instill 1 drop into the affected eye(s) once daily in the evening. 
  • Should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP-lowering effect.
  • Reduction of the IOP starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles
  • 7.5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 36° – 77°F (2° – 25°C).


223 items found

Copyright © 2019 Anadem, Inc.
3620 North High Street, Columbus, Ohio 43214 · 800.633.0055
Please send comments to Editor@EyeMedsNow.com